Contrasting Leap Therapeutics (NASDAQ:LPTX) and Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NASDAQ:ZOM)
Leap Therapeutics (NASDAQ:LPTX) and Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Leap Therapeutics and Zomedica Pharmaceuticals Corp (NYSEAMERICAN), as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Zomedica Pharmaceuticals Corp (NYSEAMERICAN)||0||0||1||0||3.00|
Earnings & Valuation
This table compares Leap Therapeutics and Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Leap Therapeutics||N/A||N/A||-$23.14 million||($2.51)||-0.76|
|Zomedica Pharmaceuticals Corp (NYSEAMERICAN)||N/A||N/A||-$16.65 million||($0.18)||-1.50|
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Leap Therapeutics has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Insider and Institutional Ownership
15.6% of Leap Therapeutics shares are held by institutional investors. Comparatively, 11.9% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by institutional investors. 36.1% of Leap Therapeutics shares are held by company insiders. Comparatively, 51.8% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Leap Therapeutics and Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Zomedica Pharmaceuticals Corp (NYSEAMERICAN)||N/A||-23,993.13%||-361.90%|
Leap Therapeutics beats Zomedica Pharmaceuticals Corp (NYSEAMERICAN) on 6 of the 10 factors compared between the two stocks.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.